Less Survivable Cancers

Clive Jones Excerpts

Tuesday 6th January 2026 Westminster Hall

[Clive Efford (in the Chair)]

I am told that the Minister is on her way, but we will proceed because so many people want to speak. I remind Members to bob if they intend to make a speech, to give me a fighting chance of working out how long each Member will have to speak. It looks like Back Benchers will have an average of three minutes each, once we start.

[Clive Jones (Wokingham) (LD) [R]]

I beg to move,

That this House has considered less survivable cancers.

It is a pleasure to serve under your chairship, Mr Efford. I declare an interest as a governor of the Royal Berkshire hospital; also, a family member has shares in a medical company. I am grateful to the Backbench Business Committee for allowing this debate, which I first asked for six months ago—[Interruption.]

[Jim Shannon (Strangford) (DUP)]

Whose phone is that?

[Clive Jones]

I apologise.

[Clive Efford (in the Chair)]

Is that the Minister calling?

[Clive Jones]

Yes, that was the Minister calling me to apologise. [Laughter.]

I asked the Committee for the debate six months ago, but having it one month before the probable publication of a national cancer plan is not a bad date for it. I also thank the less survivable cancers taskforce, Cancer Research UK and Myeloma UK for their help and guidance in securing and preparing for this debate.

As I have mentioned many times here and in the main Chamber, I am a cancer survivor. The experience has shown me how important early diagnosis and effective treatment are to our outcomes. My diagnosis was delayed, because I was sent away by the first GP I saw and had to wait several months again before being diagnosed with breast cancer. Fortunately, my treatment was successful, but many others are not so lucky, especially those with less survivable cancers.

Every year in the UK, 90,000 people are diagnosed with a less survivable cancer—cancers of the brain, liver, lungs, pancreas, oesophagus and stomach. Together, they represent 40% of all cancer deaths and account for 67,000 deaths every year. The less survivable cancers have been overlooked for far too long. While many other cancers have seen major advancements in survival, survival rates for those six cancers have remained staggeringly low for the past 25 years. The collective five-year survival rate for those cancers is just 16%. The sad reality for the 90,000 people diagnosed with one of the cancers is that 75,000 will not survive more than five years. That is a school play someone will not see, a set of exam results that they will miss, or a first day at university, a graduation, a significant birthday of their own or of a loved one, or the birth of a grandchild that someone will not see.

[Mr Gregory Campbell (East Londonderry) (DUP)]

I congratulate the hon. Gentleman on securing this debate, in particular given his personal circumstances. He rightly outlined the need for early diagnosis. Does he agree that that is particularly true of those of us who are males, who sometimes have an extreme reluctance to go to a GP to ascertain what might be wrong? That needs to be addressed urgently.

[Clive Jones]

It does. The more that people like me and others who have survived cancer talk about it, and about our experience of a delay and having the cancer spread, the more that will help others to come forward.

[Jim Dickson (Dartford) (Lab)]

I congratulate the hon. Member on securing this debate and the excellent speech he is making. He mentioned that the Government have said they will shortly publish the national cancer plan, which will include details of how they will improve outcomes for patients, speed up diagnosis and treatment, ensure that patients have access to new treatments and technology, and above all, improve cancer survival rates. Does he agree that it is critical that the plan also features key measures to address less survivable cancers, including supporting the roll-out of innovative detection tests and evaluating their use, supporting campaigns to raise awareness of symptoms, and producing a strategy for earlier and faster diagnosis?

[Clive Jones]

The hon. Member makes a very good intervention. He is absolutely right that we need to ensure that this is covered in the national cancer plan. From what I am hearing, I am optimistic that it will be.

[John Lamont (Berwickshire, Roxburgh and Selkirk) (Con)]

The hon. Member is making an excellent speech. My constituent Fiona Tweedie asked me to attend this debate because she sadly lost her husband to a brain tumour last year. She asked me to flag, in relation to the national cancer strategy, the fact that it is very difficult in Scotland to access clinical trials, and if someone is based in Scotland, they cannot access English trials. Does the hon. Member agree that this needs to be a genuinely national strategy, and that it must not allow different parts of the UK to take different directions?

[Clive Jones]

The hon. Member makes a good point; we definitely need more clinical trials in this country. We have been lagging behind in the last few years, and we need them nationally, rather than just in Scotland, Wales, England or Northern Ireland. That would be advantageous for both drug companies and the people who benefit from those trials.

For many of these less survivable cancers, survival rates in the UK lag behind other countries. We can see from our international counterparts, including Australia, Belgium, Denmark and the US, that progress is achievable, and that system reforms can play a key role in driving better patient outcomes. For example, the UK is ranked 29th out of 33 countries for pancreatic cancer survival. It is fair to ask the Minister: why is the UK ranked so low? It is also fair to ask the Conservative shadow Minister, the hon. Member for Sleaford and North Hykeham (Dr Johnson): why are we ranked so low after the Conservatives’ 14 years in Government? Perhaps it is due to the challenges in how our healthcare and cancer services are organised, and our service delivery, rather than the availability of treatment options. It is vital that we learn from our international counterparts and understand what systemic changes they have made to drive progress.

The all-party parliamentary group on less survivable cancers, of which I am a member, launched an inquiry into earlier detection and faster diagnosis. During the inquiry, the APPG heard from people with lived experience—clinicians, researchers, charities and the industry—about what vital measures are needed in the national cancer plan to improve earlier detection and faster diagnosis. The APPG found that if earlier diagnosis rates were doubled, an additional 7,500 lives would be saved every year. Deaths from those cancers could quickly be reduced by 10%.

Faster diagnosis is integral to saving lives and improving outcomes for people impacted by less survivable cancers. Simply put, it enables patients to access treatment and care much quicker, increasing their chances of survival. We are currently far from achieving this: just 28% of less survivable cancers are diagnosed at stages 1 or 2, compared with 54% for all other cancers. Concerningly, brain tumours are diagnosed in emergency settings, which is closely linked to worse outcomes.

That is common for myeloma patients—an incurable blood cancer. A third of people with myeloma are diagnosed via emergency presentation. Like the delay in diagnosing less survivable cancers, this means that their cancer has progressed untreated, and the condition has become more advanced, so their ability to tolerate treatments may be seriously hampered. The APPG’s inquiry produced some recommendations for the Government that illustrate the broad range of actions needed to achieve earlier detection and faster diagnosis, from equipping GPs with better tools and rolling out targeted screening programmes to promoting greater research into innovative diagnostics.

[Chris Coghlan (Dorking and Horley) (LD)]

I commend my hon. Friend for securing this invaluable debate. My constituent Billy was just four years old when he passed away due to DIPG—diffuse intrinsic pontine glioma—which is an incurable child brain tumour cancer. Every nine days a child is diagnosed with it. At the request of Billy’s parents I asked the Government whether there was any more they could do for brain cancer research. I am delighted that the Government have since announced that they have allocated £13.7 million in funding to the National Institute for Health and Care Research brain tumour research consortium. Does my hon. Friend agree that allocating research into rarer cancers not only benefits the children who suffer from these horrific diseases but enhances our research and development capability more broadly, clinically, which is also a vital industry for the UK?

--- Later in debate ---

[Clive Jones]

I thank my hon. Friend for his intervention; I am really sorry to hear about young Billy. The £13.7 million being put into research has to be welcomed and we should thank the Government for that.

The first recommendation is to invest in greater research, detection tests, and tools to support GPs when identifying the symptoms of less survivable cancers. GPs face difficulties in identifying vague symptoms linked to less survivable cancers, especially as they see only a small number of cases each year, and many of the symptoms overlap with those of less serious health conditions. For example, a patient with oesophageal cancer might suffer from nausea and have difficulty breathing.

I saw that lack of exposure at first hand. The first GP that I saw did not think that as a man I would be able to have breast cancer. Patients often visit their GP multiple times before being referred for further diagnostic tests. For example, currently people with pancreatic cancer visit their GP between two and five times before being referred for a CT scan. GPs lack the necessary detection tools and tests to easily identify vague symptoms earlier. But it does not have to be this way. Innovative technologies, such as Dxcover for brain cancer and Cytosponge for oesophageal cancer, are already in development and can help healthcare professionals to identify those cancers earlier and more easily.

The second recommendation is to bring together research and medical communities and establish centres of excellence for each of the less survivable cancers as key forums for knowledge sharing and collaboration. Collaboration between researchers and the medical community is essential for enhancing innovation and successfully embedding new diagnostic tools into the health system. Centres of excellence can connect specialists across research and clinical sectors, bolstering knowledge sharing and enhancing collaboration. Centres of excellence should be established by the national research community, supported by the Department of Health and Social Care and the Department for Science, Innovation and Technology. There should also be more collaboration with colleagues across the world.

Thirdly, we have to develop a centralised, nationwide case-finding programme to proactively identify high-risk individuals across multiple cancer types, building on the work already undertaken by the NHS on new onset diabetes and weight loss. To achieve faster diagnosis we must expand efforts to identify those at high risk of developing a less survivable cancer across the country. As I have already said, many healthcare professionals say every day of the week, “When cancer is detected earlier, we significantly increase patients’ chances of survival.” That is particularly true for liver cancer. When detected earlier, nearly 50% of patients with liver cancer survive for over five years compared with only 5% of those who were diagnosed at stage 4.

For those diagnosed with less survivable cancers, faster access to treatment is critical. Treatment delays cost lives. That is true of all cancers, but particularly of the less survivable ones, which progress rapidly and require specialised treatment and care. The national cancer plan offers a crucial opportunity to tackle the systemic barriers currently preventing patients from getting faster access to treatment. Variation in patient pathways, lack of diagnostic capacity and shortages across our specialist oncology and supportive care workforce have all contributed to poor access to treatment for patients affected by these cancers.

Three in four hospitals are currently failing to meet their cancer waiting time targets. According to analysis in The Guardian, 73% of trusts are failing to meet their 62-day cancer waiting time standard. One statistic I repeat time and again is that not a single NHS trust has met the 62-day target since 2015. That failure has been allowed for 10 years. It is again fair to ask the Conservative shadow Minister why, when the party was in government for so long.

This is felt more acutely for less survivable cancers, which already have some of the lowest treatment rates. For instance, 70% of people diagnosed with pancreatic cancer receive no active treatment. There is a similar picture at the Royal Berkshire hospital, where many of my constituents are patients. In 2024 alone, more than 70% of stomach cancer patients, 58% of those with pancreatic cancer and 69% of oesophageal cancer patients waited more than 62 days from urgent GP referral to treatment. That is far outside the NHS target of starting treatment for 85% within that time.

Some Royal Berkshire hospital patients are left waiting more than four months—in extreme cases more than six months—for treatment to begin, and that is not acceptable. To improve access to treatment, the Government should set tumour-specific standards through the modern service framework that has been committed to in the NHS 10-year plan, starting with the cancers with the poorest operational performance. That must include establishing minimum standards and clearer strategic priorities to support local delivery of pathway improvements for cancer.

The best way to achieve that would be to develop national, standardised, optimal pathways across the whole patient journey for different types of cancer. Where already available, those should be based on existing insight from the national clinical audits and the Getting It Right First Time programme. To achieve maximum impact, the Government must ensure that 62-day cancer waiting time targets are met and then reduced to much less than 62 days. The current standard is too low for rapidly increasing cancers such as the less survivable ones. That is crucial, because it would ensure that more people were well enough to tolerate treatment.

Research and development is also important as part of improving treatment effectiveness and diagnostics. Research into less survivable cancers has historically been underfunded, and that must change, as recognised by clinicians and many others. Isla, a constituent of my hon. Friend the Member for North East Fife (Wendy Chamberlain), has started a petition calling for more funding of research into pancreatic cancer, and it has attracted more than 200,000 signatures. Poor survival outcomes result in fewer patients taking part in clinical trials and studies, and that in turn contributes to fewer breakthroughs and less research investment—a vicious cycle that can and must be broken. Consistent, sustained research is crucial for delivering breakthroughs.

The Rare Cancers Bill, which is progressing through Parliament, has the potential to transform research into less survivable cancers. I thank the hon. Member for Edinburgh South West (Dr Arthur) for sponsoring the Bill and for all his work on cancer policy. He is a true champion for cancer patients in this Parliament. The Rare Cancers Bill is a truly groundbreaking piece of legislation that has the potential to deliver the essential research investment and focus needed to unlock breakthroughs and drive better patient outcomes. If passed, the Bill would ensure there was a named lead in the Government with a responsibility to support research and innovation for these cancers. The Bill would improve patient access to relevant research and clinical trials, and it would place a duty on the Government to review and reform orphan drug regulations to incentivise greater research into treatments for rare cancers.

The Government need to act now to improve survival outcomes for less survivable cancers. Investment and reform are needed to speed up diagnosis and improve treatment, and investment in research is essential to reaching this aim. With upcoming legislation on cancer care, there is a real opportunity for the Government to act now, to be bold and to erase the previous Government’s failure to prioritise cancer diagnosis, treatment, care and outcomes.

The Minister will know from this debate that I and many other colleagues here today, and many who are not able to attend, will be watching her actions and the actions of the Secretary of State for Health and Social Care, the Chancellor and the Prime Minister. We will be expecting results and massive improvements in the coming years.

[Several hon. Members rose—]

--- Later in debate ---

[Clive Jones]

I thank the Minister very much for her interesting response. I thank all Members who contributed to the debate, many of whom spoke very personally about their own experiences. From time to time, that can be quite a hard thing to do, so I thank everybody for doing so. In particular, I thank the hon. Member for Southport (Patrick Hurley), who spoke very movingly.

I hope the Minister has taken note of all the things that have come out of the debate. There is a need for better diagnosis and for new and more drug trials; there is a need to share information among organisations and across borders; there is a need for better screening of cancer; there is a need for big improvements in the workforce; there is a need for better equipment and new technologies; and there is a need to embrace innovation.

I was pleased to hear that the national cancer plan is still probably going to be announced sometime in February—maybe 4 February—and that it has not been delayed. Everybody is looking forward to seeing that plan. Not just those of us who have come to this debate, but many MPs who have not been able to attend, and millions of our constituents, will be looking to see what is in the national cancer plan. We really hope it covers all the things we have been asking for to date—all the things that the APPGs have been asking for and that individual Members have had meetings with the Minister and others about. All I can say on behalf of the people who have an interest in cancer is that we really hope the Government have been listening, and that it is a cancer plan that everybody in the House is able to get behind—one that will improve diagnosis, treatment and outcomes for people in this country suffering with the most awful diseases. I thank everyone very much for attending the debate.

Question put and agreed to.

Resolved,

That this House has considered less survivable cancers.